Skip to content

Orphan Drugs Industry Advisory & Intelligence

Pulse

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case

Posted on May 2, 2016May 2, 2016 by christian@orphandrugsindustry.com

Link to article

Posted in PulseTagged Big pharma, Orphan drugs, Rare diseases

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case

Posted on April 26, 2016May 1, 2016 by christian@orphandrugsindustry.com

Link to article

Posted in PulseTagged Big pharma, Orphan drugs, Rare diseases

Headquarter

1, rue Roch ar Ruguel
29680 Roscoff, France
Tel: +33 (0)6 67 26 60 92
Create a website or blog at WordPress.com